DekaBank Deutsche Girozentrale Acquires 5,425 Shares of Thermo Fisher Scientific Inc. $TMO

DekaBank Deutsche Girozentrale lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 772,643 shares of the medical research company’s stock after buying an additional 5,425 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Thermo Fisher Scientific were worth $317,498,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Journey Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $2,611,000. Canvas Wealth Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 170.2% during the 2nd quarter. Canvas Wealth Advisors LLC now owns 1,394 shares of the medical research company’s stock valued at $565,000 after buying an additional 878 shares in the last quarter. Lyell Wealth Management LP grew its holdings in Thermo Fisher Scientific by 4.3% during the 2nd quarter. Lyell Wealth Management LP now owns 32,114 shares of the medical research company’s stock valued at $13,021,000 after buying an additional 1,333 shares in the last quarter. Accretive Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 1.3% during the 2nd quarter. Accretive Wealth Partners LLC now owns 3,248 shares of the medical research company’s stock valued at $1,317,000 after buying an additional 41 shares in the last quarter. Finally, Cidel Asset Management Inc. grew its holdings in Thermo Fisher Scientific by 14.0% during the 2nd quarter. Cidel Asset Management Inc. now owns 1,560 shares of the medical research company’s stock valued at $633,000 after buying an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.4%

Shares of TMO opened at $539.05 on Monday. The firm has a market capitalization of $203.55 billion, a P/E ratio of 31.18, a P/E/G ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average price of $495.74 and a 200-day moving average price of $448.98.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Barclays increased their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Raymond James Financial reissued an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.